Passive immunization as tool to identify protective HIV-1 env epitopes

Victor G. Kramer, Nagadenahalli B. Siddappa, Ruth M. Ruprecht

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

The HIV-1/AIDS epidemic continues to escalate, and a protective vaccine remains elusive. The first vaccine candidate, gp120, did not induce broadly neutralizing antibodies (nAbs) against primary HIV-1 isolates and was ineffective in phase III clinical trials. Attention then focused on generating cytotoxic lymphocyte (CTL)-based vaccines. Interest in anti-HIV-1 nAbs was renewed when passive immunization with human neutralizing monoclonal antibodies (nmAbs) completely protected macaques after intravenous and mucosal challenges with simian-human immunodeficiency viruses (SHIVs) encoding HIV-1 env. These nmAbs targeted conserved, functionally important epitopes on gp120 and gp4l. Protection in primate/SHIV models was observed when nmAbs were used singly (nmAbs 2G12, b12) and in various combination regimens (nmAbs b12, F105, 2G12, 2F5, 4E10). Passive immunization, a well-established tool to determine the correlates of protective immunity, thus identified protective epitopes. The three-dimensional structures of some of the latter were recently elucidated, generating important information to design nAb-response-base immunogens. However, several of the protective nmAbs were found to exhibit autoreactivity, raising the possibility that B-cell responses against the cognate epitopes may be difficult to induce by active immunization. It will be important to explore whether broab neutralization can be dissociated from autoreactivity. Future experiments will reveal whether other conserved HIV-1 Env epitopes exist, antibodies against which will be broadly neutralizing in vitro, protective as passive immunization in SHIV-challenged macaques, but lacking autoreactivity. Since all protective epitopes identified to date are 1ocated on HIV-1 clade B Env, future studies should include analysis of nmAbs against non-clade B strains.

Original languageEnglish (US)
Pages (from-to)642-655
Number of pages14
JournalCurrent HIV research
Volume5
Issue number6
DOIs
StatePublished - Nov 1 2007

Fingerprint

Passive Immunization
Neutralizing Antibodies
HIV-1
Epitopes
Monoclonal Antibodies
Simian Immunodeficiency Virus
Vaccines
HIV
Macaca
Phase III Clinical Trials
Primates
Immunity
Vaccination
Acquired Immunodeficiency Syndrome
B-Lymphocytes
Lymphocytes
Antibodies

Keywords

  • Epitopes
  • Neutralizing antibodies
  • Passive immunization
  • SHIV

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

Passive immunization as tool to identify protective HIV-1 env epitopes. / Kramer, Victor G.; Siddappa, Nagadenahalli B.; Ruprecht, Ruth M.

In: Current HIV research, Vol. 5, No. 6, 01.11.2007, p. 642-655.

Research output: Contribution to journalReview article

Kramer, Victor G. ; Siddappa, Nagadenahalli B. ; Ruprecht, Ruth M. / Passive immunization as tool to identify protective HIV-1 env epitopes. In: Current HIV research. 2007 ; Vol. 5, No. 6. pp. 642-655.
@article{f341c3cdccbb43c09b41a0e19758bf4e,
title = "Passive immunization as tool to identify protective HIV-1 env epitopes",
abstract = "The HIV-1/AIDS epidemic continues to escalate, and a protective vaccine remains elusive. The first vaccine candidate, gp120, did not induce broadly neutralizing antibodies (nAbs) against primary HIV-1 isolates and was ineffective in phase III clinical trials. Attention then focused on generating cytotoxic lymphocyte (CTL)-based vaccines. Interest in anti-HIV-1 nAbs was renewed when passive immunization with human neutralizing monoclonal antibodies (nmAbs) completely protected macaques after intravenous and mucosal challenges with simian-human immunodeficiency viruses (SHIVs) encoding HIV-1 env. These nmAbs targeted conserved, functionally important epitopes on gp120 and gp4l. Protection in primate/SHIV models was observed when nmAbs were used singly (nmAbs 2G12, b12) and in various combination regimens (nmAbs b12, F105, 2G12, 2F5, 4E10). Passive immunization, a well-established tool to determine the correlates of protective immunity, thus identified protective epitopes. The three-dimensional structures of some of the latter were recently elucidated, generating important information to design nAb-response-base immunogens. However, several of the protective nmAbs were found to exhibit autoreactivity, raising the possibility that B-cell responses against the cognate epitopes may be difficult to induce by active immunization. It will be important to explore whether broab neutralization can be dissociated from autoreactivity. Future experiments will reveal whether other conserved HIV-1 Env epitopes exist, antibodies against which will be broadly neutralizing in vitro, protective as passive immunization in SHIV-challenged macaques, but lacking autoreactivity. Since all protective epitopes identified to date are 1ocated on HIV-1 clade B Env, future studies should include analysis of nmAbs against non-clade B strains.",
keywords = "Epitopes, Neutralizing antibodies, Passive immunization, SHIV",
author = "Kramer, {Victor G.} and Siddappa, {Nagadenahalli B.} and Ruprecht, {Ruth M.}",
year = "2007",
month = "11",
day = "1",
doi = "10.2174/157016207782418506",
language = "English (US)",
volume = "5",
pages = "642--655",
journal = "Current HIV Research",
issn = "1570-162X",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Passive immunization as tool to identify protective HIV-1 env epitopes

AU - Kramer, Victor G.

AU - Siddappa, Nagadenahalli B.

AU - Ruprecht, Ruth M.

PY - 2007/11/1

Y1 - 2007/11/1

N2 - The HIV-1/AIDS epidemic continues to escalate, and a protective vaccine remains elusive. The first vaccine candidate, gp120, did not induce broadly neutralizing antibodies (nAbs) against primary HIV-1 isolates and was ineffective in phase III clinical trials. Attention then focused on generating cytotoxic lymphocyte (CTL)-based vaccines. Interest in anti-HIV-1 nAbs was renewed when passive immunization with human neutralizing monoclonal antibodies (nmAbs) completely protected macaques after intravenous and mucosal challenges with simian-human immunodeficiency viruses (SHIVs) encoding HIV-1 env. These nmAbs targeted conserved, functionally important epitopes on gp120 and gp4l. Protection in primate/SHIV models was observed when nmAbs were used singly (nmAbs 2G12, b12) and in various combination regimens (nmAbs b12, F105, 2G12, 2F5, 4E10). Passive immunization, a well-established tool to determine the correlates of protective immunity, thus identified protective epitopes. The three-dimensional structures of some of the latter were recently elucidated, generating important information to design nAb-response-base immunogens. However, several of the protective nmAbs were found to exhibit autoreactivity, raising the possibility that B-cell responses against the cognate epitopes may be difficult to induce by active immunization. It will be important to explore whether broab neutralization can be dissociated from autoreactivity. Future experiments will reveal whether other conserved HIV-1 Env epitopes exist, antibodies against which will be broadly neutralizing in vitro, protective as passive immunization in SHIV-challenged macaques, but lacking autoreactivity. Since all protective epitopes identified to date are 1ocated on HIV-1 clade B Env, future studies should include analysis of nmAbs against non-clade B strains.

AB - The HIV-1/AIDS epidemic continues to escalate, and a protective vaccine remains elusive. The first vaccine candidate, gp120, did not induce broadly neutralizing antibodies (nAbs) against primary HIV-1 isolates and was ineffective in phase III clinical trials. Attention then focused on generating cytotoxic lymphocyte (CTL)-based vaccines. Interest in anti-HIV-1 nAbs was renewed when passive immunization with human neutralizing monoclonal antibodies (nmAbs) completely protected macaques after intravenous and mucosal challenges with simian-human immunodeficiency viruses (SHIVs) encoding HIV-1 env. These nmAbs targeted conserved, functionally important epitopes on gp120 and gp4l. Protection in primate/SHIV models was observed when nmAbs were used singly (nmAbs 2G12, b12) and in various combination regimens (nmAbs b12, F105, 2G12, 2F5, 4E10). Passive immunization, a well-established tool to determine the correlates of protective immunity, thus identified protective epitopes. The three-dimensional structures of some of the latter were recently elucidated, generating important information to design nAb-response-base immunogens. However, several of the protective nmAbs were found to exhibit autoreactivity, raising the possibility that B-cell responses against the cognate epitopes may be difficult to induce by active immunization. It will be important to explore whether broab neutralization can be dissociated from autoreactivity. Future experiments will reveal whether other conserved HIV-1 Env epitopes exist, antibodies against which will be broadly neutralizing in vitro, protective as passive immunization in SHIV-challenged macaques, but lacking autoreactivity. Since all protective epitopes identified to date are 1ocated on HIV-1 clade B Env, future studies should include analysis of nmAbs against non-clade B strains.

KW - Epitopes

KW - Neutralizing antibodies

KW - Passive immunization

KW - SHIV

UR - http://www.scopus.com/inward/record.url?scp=38949206356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949206356&partnerID=8YFLogxK

U2 - 10.2174/157016207782418506

DO - 10.2174/157016207782418506

M3 - Review article

C2 - 18045119

AN - SCOPUS:38949206356

VL - 5

SP - 642

EP - 655

JO - Current HIV Research

JF - Current HIV Research

SN - 1570-162X

IS - 6

ER -